Strategy for selection of first-line therapy for progressive CLL.

† If used to treat disease-related symptoms; liberal dose reductions.

‡ Indicates our recommended approach for patients with AIHA who also meet NCI 96 criteria for treatment. In patients with AIHA for whom hemolysis is the only indication for treatment, hemolytic anemia can often be successfully managed with immunosuppressive therapies.

Abbreviations: AIHA, autoimmune hemolytic anemia.